WO2006026619A3 - Inhibition of viruses using rnase h inhibitors - Google Patents

Inhibition of viruses using rnase h inhibitors Download PDF

Info

Publication number
WO2006026619A3
WO2006026619A3 PCT/US2005/030846 US2005030846W WO2006026619A3 WO 2006026619 A3 WO2006026619 A3 WO 2006026619A3 US 2005030846 W US2005030846 W US 2005030846W WO 2006026619 A3 WO2006026619 A3 WO 2006026619A3
Authority
WO
WIPO (PCT)
Prior art keywords
rnase
inhibitors
viruses
inhibition
aminocarbonyl
Prior art date
Application number
PCT/US2005/030846
Other languages
French (fr)
Other versions
WO2006026619A2 (en
Inventor
John Beutler
Stuart F J Legrice
Scott R Budihas
Anthony Wamiru
Roberta Gardella
Jennifer Wilson
Katya Goncharova
Original Assignee
Us Health
John Beutler
Stuart F J Legrice
Scott R Budihas
Anthony Wamiru
Roberta Gardella
Jennifer Wilson
Katya Goncharova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, John Beutler, Stuart F J Legrice, Scott R Budihas, Anthony Wamiru, Roberta Gardella, Jennifer Wilson, Katya Goncharova filed Critical Us Health
Priority to AU2005279845A priority Critical patent/AU2005279845A1/en
Priority to EP05803872A priority patent/EP1796662A2/en
Priority to CA002579089A priority patent/CA2579089A1/en
Publication of WO2006026619A2 publication Critical patent/WO2006026619A2/en
Publication of WO2006026619A3 publication Critical patent/WO2006026619A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to methods and compositions for the treatment of viral infections including HIV using RNase H inhibitors. Compounds are e.g. 2-amino-5,6,7,8-tetrahydro-4H-cyclohepta (b) thiophene-3-carboxamide, N-(3-(aminocarbonyl)-4,5-dimehtyl-2-thienyl)-2-furamide, N-(3-(aminocarbonyl)-4,5-dimethyl-2-thienyl)-tetrahydro-2-furancarboxamide, etc.
PCT/US2005/030846 2004-08-30 2005-08-30 Inhibition of viruses using rnase h inhibitors WO2006026619A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2005279845A AU2005279845A1 (en) 2004-08-30 2005-08-30 Inhibition of viruses using RNase H inhibitors
EP05803872A EP1796662A2 (en) 2004-08-30 2005-08-30 Inhibition of viruses using rnase h inhibitors
CA002579089A CA2579089A1 (en) 2004-08-30 2005-08-30 Inhibition of viruses using rnase h inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60516504P 2004-08-30 2004-08-30
US60/605,165 2004-08-30

Publications (2)

Publication Number Publication Date
WO2006026619A2 WO2006026619A2 (en) 2006-03-09
WO2006026619A3 true WO2006026619A3 (en) 2006-05-04

Family

ID=35744862

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/030846 WO2006026619A2 (en) 2004-08-30 2005-08-30 Inhibition of viruses using rnase h inhibitors

Country Status (4)

Country Link
EP (1) EP1796662A2 (en)
AU (1) AU2005279845A1 (en)
CA (1) CA2579089A1 (en)
WO (1) WO2006026619A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA022521B1 (en) 2010-04-28 2016-01-29 Астеллас Фарма Инк. Tetrahydrobenzothiophene compounds, pharmaceutical composition based thereon, use thereof and method for treating hyperphosphatemia
WO2012167011A1 (en) 2011-06-02 2012-12-06 Massachusetts Institute Of Technology Dsrna/dna hybrid genome replication intermediate of metakaryotic stem cells
JP6020460B2 (en) 2011-10-27 2016-11-02 アステラス製薬株式会社 Aminoalkyl-substituted N-thienylbenzamide derivatives
WO2014179786A1 (en) 2013-05-03 2014-11-06 Inscent, Inc. Improved honeybee repellents and uses thereof
WO2014179785A1 (en) * 2013-05-03 2014-11-06 Inscent, Inc. Improved honeybee repellents and uses thereof
EP3562818B1 (en) 2016-12-29 2022-05-18 ENYO Pharma Thiophene derivatives as antiviral agents
EP3612180B1 (en) * 2017-04-17 2023-10-11 The Regents of the University of California Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel tmem16a
US20220000864A1 (en) * 2018-11-19 2022-01-06 11949098 Canada Inc. MODULATORS OF RAR-RELATED ORPHAN RECEPTORS (RORs)

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997027200A1 (en) * 1996-01-26 1997-07-31 Smithkline Beecham Plc Thienoxazinone derivatives useful as antiviral agents
WO1998037880A1 (en) * 1997-02-26 1998-09-03 Ciblex Corporation Inhibitors of leaderless protein export
WO1998045298A1 (en) * 1997-04-10 1998-10-15 Smithkline Beecham Plc Antiviral agents
WO2001098290A2 (en) * 2000-06-19 2001-12-27 Pharmacia Italia S.P.A. Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
EP1352650A1 (en) * 2000-12-18 2003-10-15 Institute of Medicinal Molecular Design, Inc. Inhibitors against the production and release of inflammatory cytokines
WO2004009582A1 (en) * 2002-07-19 2004-01-29 Pharmacia Corporation Substituted thiophene carboxamide compounds for the treatment of inflammation
WO2004032827A2 (en) * 2002-05-20 2004-04-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2004089360A1 (en) * 2003-04-02 2004-10-21 Taigen Biotechnology Polyamine compounds for treating chemokine receptor mediated diseases
WO2005027882A1 (en) * 2003-09-22 2005-03-31 Bionetworks Gmbh Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
WO2005060711A2 (en) * 2003-12-19 2005-07-07 Elixir Pharmaceuticals, Inc. Methods of treating a disorder
WO2005072412A2 (en) * 2004-01-29 2005-08-11 Elixir Pharmaceuticals, Inc. Anti-viral therapeutics

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997027200A1 (en) * 1996-01-26 1997-07-31 Smithkline Beecham Plc Thienoxazinone derivatives useful as antiviral agents
WO1998037880A1 (en) * 1997-02-26 1998-09-03 Ciblex Corporation Inhibitors of leaderless protein export
WO1998045298A1 (en) * 1997-04-10 1998-10-15 Smithkline Beecham Plc Antiviral agents
WO2001098290A2 (en) * 2000-06-19 2001-12-27 Pharmacia Italia S.P.A. Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
EP1352650A1 (en) * 2000-12-18 2003-10-15 Institute of Medicinal Molecular Design, Inc. Inhibitors against the production and release of inflammatory cytokines
WO2004032827A2 (en) * 2002-05-20 2004-04-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2004009582A1 (en) * 2002-07-19 2004-01-29 Pharmacia Corporation Substituted thiophene carboxamide compounds for the treatment of inflammation
WO2004089360A1 (en) * 2003-04-02 2004-10-21 Taigen Biotechnology Polyamine compounds for treating chemokine receptor mediated diseases
WO2005027882A1 (en) * 2003-09-22 2005-03-31 Bionetworks Gmbh Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
WO2005060711A2 (en) * 2003-12-19 2005-07-07 Elixir Pharmaceuticals, Inc. Methods of treating a disorder
WO2005072412A2 (en) * 2004-01-29 2005-08-11 Elixir Pharmaceuticals, Inc. Anti-viral therapeutics

Also Published As

Publication number Publication date
WO2006026619A2 (en) 2006-03-09
EP1796662A2 (en) 2007-06-20
AU2005279845A1 (en) 2006-03-09
CA2579089A1 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
WO2006026619A3 (en) Inhibition of viruses using rnase h inhibitors
WO2005087731A8 (en) Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
EP1924593B8 (en) Hcv ns3 protease inhibitors
WO2005051980A8 (en) Depeptidized inhibitors of hepatitis c virus ns3 protease
WO2006119061A3 (en) Hcv ns3 protease inhibitors
WO2004041201A3 (en) Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
WO2007092645A3 (en) Novel hcv inhibitor combinations and methods
WO2006066079A3 (en) Pyridazinone compounds
WO2008057208A3 (en) Hcv ns3 protease inhibitors
WO2008051514A3 (en) Hcv ns3 protease inhibitors
WO2008051475A3 (en) Hcv ns3 protease inhibitors
WO2007076034A3 (en) Anti-viral compounds
WO2005087725A3 (en) Novel compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2007070556A3 (en) N-(6-membered aromatic ring)-amido anti-viral compounds
CA2473070A1 (en) Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection
WO2006081554A3 (en) Phenyl-substituted pyrrolidones
MX2009006880A (en) 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections.
DE602005027580D1 (en) INHIBITORS OF THE RNA-DEPENDENT RNA POLYMERASE OF HEPATITIS C VIRUS AND COMPOSITIONS AND TREATMENTS THEREOF WHERE THEY ARE USED
WO2007140200A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2007084413A3 (en) Methods for treating hepatitis c
WO2004110351A3 (en) Heterocyclic compounds for treating hepatitis c virus
WO2008115281A3 (en) Compounds for treating viral infections
WO2004041203A3 (en) Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
NO20062146L (en) Nucleoside compounds for the treatment of viral infections
WO2001077091A3 (en) Ns5b hcv polymerase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005803872

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2579089

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005279845

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005279845

Country of ref document: AU

Date of ref document: 20050830

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005279845

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005803872

Country of ref document: EP